66 results
The primary objective is to compare the effectiveness of ambroxol versus placebo on the MDS-UPDRS part III motor sub-score in the *practically defined OFF-medication state* in patients with moderate PD, carrying a GBA mutation. The hypothesis is…
The main objective of the current study is to assess the impact of dietary collagen supplementation on human tendon protein synthesis.
In this study we will investigate how safe the new compound ARGX-119 is and how well it is tolerated when it is used by healthy subjects.We also investigate how quickly and to what extent ARGX-119 is distributed and eliminated from the body. In…
Primary objective* To assess the efficacy of EP547 compared to placebo on pruritus as assessed by the Worst Itch Numeric Rating Scale (WI-NRS)Secondary* To assess the efficacy of EP547 compared to placebo on the following:* Pruritus-related quality…
The main objectives Investigate a first signal of efficacy, safety and tolerability of BI 706321 in combination with ustekinumab treatment compared to placebo with ustekinumab treatment in patients with moderately to severely active CD at 12 weeks.…
To investigate whether 3 monthly Dmab will improve the clinical, radiological and biochemical manifestations of FD bone lesions.
To study whether ziltivekimab therapy reduces arterial wall inflammation as assessed by imaging, and reduces the systemic inflammatory tone as assessed by circulating monocytes, inflammatory biomarkers and proteomics.
To examine the effect of oral dasatinib plus quercetin on liver fibrosis as assessed by histology in individuals with biopsy-proven NAFLD with fibrosis by performing a double*blind randomized controlled proof*of*principle study. The primary endpoint…
To investigate the feasibility of a combination therapy (consisting of individualized rTMS and cognitive strategy training) and study measurements in patients with a primary brain tumor during stable disease. The study is considered feasible when 80…
Primary Efficacy Objective (Blinded Treatment Period)• To demonstrate the efficacy of rilzabrutinib versus placebo in participants with refractory/relapsed ITP, based on the durability of platelet response during the last12 weeks of the 24-week…
This study will evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of crovalimab compared with placebo for the management of acute uncomplicated vaso-occlusive episodes (VOE) in patients with sickle cell disease (SCD).
To explore the safety, feasibility and net symptomatic effects of multiple intermittent hypoxia intervention sessions in individuals with PD. Secondary outcomes include exploring induction of relevant neuroprotective pathways as measured in serum.
To assess safety, pharmacokinetics and efficacy of oral dosage of 6-BT in individuals with metabolic syndrome
To explore the effect of reversible virtual lesions on cognitive functioning in the domain of executive functioning and on network organization / to define local network resilience and the interplay between local resilience and global network…
To follow up on the previous study on PBM effects on well-being by prospectively assessing mood, drowsiness and depression as well as energy/tiredness/tension/calmness, and sleep parameters, and on health by prospectively assessing resting heart…
Part 1:To evaluate the effects of 52 weeks of treatment with basmisanil on core symptom domains of Dup15q syndrome (language and social skills) and dailyfunctioning. Part 2:• To evaluate the tolerability and safety of up to 3 years of treatment with…
This study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of crovalimab compared with placebo as adjunct treatment for the prevention of vaso-occlusive episodes (VOEs) in patients with sickle cell disease (SCD).
OBJECTIVES - Phase 2 (not to be conducted in NL):Phase 2 Primary Objective:- Identify a setrusumab dosing strategy in subjects with OI Phase 2 Secondary Objectives:- Evaluate the PK of setrusumab doses in subjects with OI- Determine the PD effects…
To investigate the effect of daily intake of 350 milligrams of magnesium citrate oral supplementation over a period of six months on calciprotein particle maturation time (T50) in serum, a measure of calcification propensity, and on vascular…